HoyleCohen’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-4,147
Closed -$401K 294
2024
Q1
$401K Buy
4,147
+229
+6% +$23.5K 0.03% 213
2023
Q4
$396K Hold
3,918
0.03% 210
2023
Q3
$399K Buy
3,918
+225
+6% +$22.8K 0.04% 196
2023
Q2
$373K Hold
3,693
0.03% 203
2023
Q1
$340K Sell
3,693
-1,000
-21% -$87.3K 0.03% 209
2022
Q4
$426K Sell
4,693
-467
-9% -$39.3K 0.04% 195
2022
Q3
$392K Sell
5,160
-99
-2% -$8.21K 0.04% 190
2022
Q2
$445K Sell
5,259
-94
-2% -$8.25K 0.05% 185
2022
Q1
$470K Sell
5,353
-220
-4% -$19K 0.04% 193
2021
Q4
$487K Buy
5,573
+651
+13% +$54.1K 0.04% 196
2021
Q3
$403K Hold
4,922
0.04% 198
2021
Q2
$449 Sell
4,922
-15
-0.3% -$1.34K 0.04% 192
2021
Q1
$422K Sell
4,937
-185
-4% -$16.6K 0.04% 191
2020
Q4
$484K Sell
5,122
-150
-3% -$13.1K 0.06% 165
2020
Q3
$458K Buy
5,272
+200
+4% +$17.3K 0.07% 142
2020
Q2
$443K Hold
5,072
0.07% 131
2020
Q1
$418K Sell
5,072
-40
-0.8% -$3.57K 0.08% 132
2019
Q4
$484K Hold
5,112
0.08% 141
2019
Q3
$444K Hold
5,112
0.08% 147
2019
Q2
$467K Buy
5,112
+1,779
+53% +$151K 0.08% 141
2019
Q1
$287K Buy
3,333
+687
+26% +$55.2K 0.05% 157
2018
Q4
$203K Hold
2,646
0.04% 161
2018
Q3
$204K Buy
+2,646
New +$196K 0.04% 163
2018
Q2
Sell
-3,316
Closed -$240K 163
2018
Q1
$240K Sell
3,316
-237
-7% -$18K 0.05% 142
2017
Q4
$267K Buy
+3,553
New +$268K 0.05% 139

Other funds holding NVS

HoyleCohen's NVS Position: Q2 2024 in Review

HoyleCohen sold out of Novartis (NVS) in Q2 2024, closing a stake of 4,147 shares — an estimated $401K sold.

HoyleCohen first reported a position in NVS in Q4 2017 and held it in 25 quarters. The position peaked at $487K in Q4 2021. 1,306 funds tracked by Wall St. Rank hold NVS as of Q2 2024.

  • HoyleCohen reported no remaining Novartis position as of Q2 2024 after selling out during the quarter.
  • HoyleCohen sold 4,147 Novartis shares in Q2 2024, an estimated $401K.
  • HoyleCohen first reported a position in Novartis in Q4 2017 and held it in 25 quarters.
  • HoyleCohen's Novartis position peaked at $487K in Q4 2021.
  • 1,306 funds tracked by Wall St. Rank held Novartis as of Q2 2024.

Based on HoyleCohen's 13F filing for Q2 2024, filed 19 Jul 2024.